Gastric tumours in hereditary cancer syndromes: Clinical features, molecular biology and strategies for prevention

Clinical and Translational Oncology

Volumn 13, Issue 9, 2011, Pages 599-610

  Sereno, María ^a,c   Aguayo, Cristina ^a   Guillén Ponce, Carmen ^b   Gómez Raposo, César ^a   Zambrana, Francisco ^a   Gómez López, Miriam ^a   Casado, Enrique ^a  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Urb Las Azaleas Fresno Norte   (Spain)

Author keywords

Diffuse gastric cancer; Hereditary gastric cancer

Indexed keywords

BETA CATENIN; BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN KINASE LKB1; PROTEIN MLH1; UVOMORULIN;

ADENOMATOUS POLYP; ADENOMATOUS POLYPOSIS GENE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CDH1 GENE; CLINICAL FEATURE; FAMILIAL CANCER; FAMILIAL INTESTINAL GASTRIC CARCINOMA; GASTRECTOMY; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MLH1 GENE; MOLECULAR PATHOLOGY; MUTATOR GENE; OVARY CANCER; PEUTZ JEGHERS SYNDROME; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH TUMOR; STRATEGIC PLANNING; TUMOR SUPPRESSOR GENE; BIOLOGICAL MODEL; CARCINOMA; COLON POLYPOSIS; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY; MOLECULAR BIOLOGY; PATHOLOGY; PREVENTIVE MEDICINE; REVIEW;

ADENOMATOUS POLYPOSIS COLI; CARCINOMA; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR BIOLOGY; NEOPLASTIC SYNDROMES, HEREDITARY; PREVENTIVE MEDICINE; STOMACH NEOPLASMS;

EID: 84855391821     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0705-y     Document Type: Article

References (67)

1. Fitzgerald R, Hardwick D, Huntsman D et al (2010) Behalf of the International Gastric Cancer Linkage Consortium. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research J Med Genet 47:436
2. Guilford P, Bostjan H, Blair V (2010) Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 13:1-10
3. Hebbard PC, MacMillan A, Huntsman D et al (2009) Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland Experience with 23 Patients. Ann Surg Oncol 16:1890-1895
4. Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402-405 (Pubitemid 28168738)
5. Oliveira C, Sousa S, Pinheiro H et al (2009) Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 136:2137
6. Guilford P, Humar B, Blair V (2010) Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 13:1-10
7. Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681-687 (Pubitemid 38714105)
8. Barber ME, Save V, Carneiro F et al (2008) Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 216:286-294
9. Charlton A, Blair V, Shaw D et al (2004) Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53: 814-820 (Pubitemid 38662130)
10. Barber ME, Save V, Carneiro F et al (2008) Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 216:12-18
11. Charlton A, Blair V, Shaw D et al (2004) Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53:814
12. Norton JA, Ham CM, Dam JV et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873-879 (Pubitemid 46809288)
13. Robin M. Cisco, James M et al (2008) Hereditary diffuse gastric cancer implications of genetic testing for screening and prophylactic surgery. Cancer 1:7
14. Ano T, Kobori O, Muto T (1992) Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 79:241-244
15. Lewis FR, Mellinger JD, Hayashi A et al (2001) Prophylactic total gastrectomy for familial gastric cancer. Surgery 130:612-617
16. Chun YS, Lindor NM, Smyrk TC et al (2001) Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 92:181-187 (Pubitemid 32623055)
17. Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100:1658-1664
18. Lanch KL, Buerke CA, Bennett AE et al (2008) Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Heptatol 6:180-185 (Pubitemid 351172948)
19. Spigelman AD, Williams CB, Talbot IC et al (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2:783-785 (Pubitemid 19234818)
20. Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100:1658-1664
21. Half E, Bercovich D, Rozen P (2009) Familial adenomatous polyposis. Orphanet J Rare Dis 4:22
22. Abraham SC, Nobukawa B, Giardiello FM et al (2000) Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 157:747-754 (Pubitemid 32109367)
23. Toyooka M, Konishi M, Kikuchi-Yanoshita R et al (1995) Somatic mutations of the adenomatous polyposis coli gene in gastroduodenal tumors from patients with familial adenomatous polyposis. Cancer Res 55:3165-3170
24. Gallagher MC, Phillips RK, Bulow S et al (2006) Surveillance and management of upper gastrointestinal disease in familial adenomatous polyposis. Familial Cancer 5:263-273 (Pubitemid 44453857)
25. Debinski HS, Spigelman AD, Hatfield A et al (1995) Upper intestinal surveillance in familial adenomatous polyposis. Eur J Cancer 31:1149-1153
26. Church JM, McGannon E, Hull-Boiner S et al (1992) Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum 35:1170-1173
27. Offerhaus GJ, Giardiello FM, Krush AJ et al (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980-1982
28. Domizio P, Talbot IC, Spigelman AD et al (1990) Upper gastrointestinal pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. J Clin Pathol 43:738-743 (Pubitemid 20279702)
29. Debinski HS, Spigelman AD, Hatfield A et al (1995) Upper intestinal surveillance in familial adenomatous polyposis. Eur J Cancer 31A:1149-1153
30. Zwick A, Munir M, Ryan CK et al (1997) Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 113:659-663 (Pubitemid 27351795)
31. Bulow S, Bjork J, Christensen IJ et al (2004) Duodenal adenomatosis in familial adenomatous polyposis. Gut 53:381-386 (Pubitemid 38241334)
32. Spigelman AD, Williams CB, Talbot IC et al (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2:783-785 (Pubitemid 19234818)
33. Bülow S, Björk J, Christensen IJ et al (2004) DAF Study Group: duodenal adenomatosis in familial adenomatous polyposis. Gut 53:381-386 (Pubitemid 38241334)
34. Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952 (Pubitemid 30419089)
35. Giardiello FM, Hylind LM, Trimbath JD et al (2005) Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 128:1077-1080 (Pubitemid 40523557)
36. Müller MW, Dahmen R, Köninger J et al (2008)) Is there an advantage in performing a pancreaspreserving total duodenectomy in duodenal adenomatosis? Am J Surg 195:741-748 (Pubitemid 351749461)
37. Cai SJ, Xu Y, Cai GX et al (2003) Clinical characteristics and diagnosis of patients with hereditary nonpolyposis colorectal cancer. World J Gastroenterol 9:284-287 (Pubitemid 36215805)
38. Lynch HT, Lynch PM, Lanspa SJ et al (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifi cations. Clin Genet 76:1-18
39. Caldas C, Carneiro F, Lynch HT et al (1999) Familial gastric cancer: overview and guidelines for management. Med Genet 36:873-880 (Pubitemid 30003842)
40. Bonis PA, Trikalinos TA, Chung M et al (2007) Clinical characteristics and diagnosis of patients with hereditary nonpolyposis colorectal cancer. Evid Rep Technol Assess 150:1-180
41. Rodriguez-Bigas MA, Boland CR, Hamilton SR et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758-1762
42. Fitzgerald RC, Caldas C (2006) Familial gastric cancer: clinical management. Best Pract Res Clin Gastroenterol 20:735-743 (Pubitemid 44403453)
43. Markku A, Risto S, Eero P et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218
44. Gylling AH, Nieminen TT, Abdel-Rahman WM et al (2008) Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 29:1351-1359
45. Watson P, Vasen H, Mecklin JM et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444-449 (Pubitemid 351842032)
46. Winawer S, Fletcher R, Rex D et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 124:544-560 (Pubitemid 36169269)
47. Lynch HT, Lynch PM, Lanspa SJ (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifi cations. Clin Genet 76:1-18
48. Gylling A, Abdel-Rahman WM, Juhola M (2007) Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut 56:926-933 (Pubitemid 46999075)
49. Van Vansen Best surveillance protocol for Lynch syndrome?. The Netherlands hereditary cancer Registry (2005) Insight meeting, Newcastle, United Kingdom, June 2005
50. Lynch HT, Casey MJ (2007) Prophylactic surgery prevents endometrial and ovarian cancer in Lynch syndrome. Nat Clin Pract Oncol 4:672-673 (Pubitemid 350186997)
51. Schreibman IR, Baker M, Amos C et al (2005) The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol 100:476-490 (Pubitemid 40314537)
52. Giardiello FM, Brensinger JD, Tersmette AC et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447
53. Konishi F, Wyse NE, Muto T et al (1987) Peutz-Jeghers polyposis associated with carcinoma of the digestive organs. Report of three cases and review of the literature. Dis Colon Rectum 30: 790
54. Giardiello FM, Hamilton SR, Kern SE et al (1991) Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Childhood 66:971
55. Defago MR, Higa AL, Campra JL et al (1996) Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Endoscopy 28:267 (Pubitemid 26136932)
56. Giardiello FM, Trimbath JD (2006) Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 4:408
57. Soares J, Lopes L, Vilas Boas G et al (2004) Wireless capsule endoscopy for evaluation of phenotypic expression of small-bowel polyps in patients with Peutz-Jeghers syndrome and in symptomatic fi rst-degree relatives. Endoscopy 36:1060
58. Hearle N, Schumacher V, Menko FH et al (2006) Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12:3209-3215 (Pubitemid 43837371)
59. Gianfagna F, De Feo E, van Duijn CM et al (2008) A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr Genomics 9:361-374
60. Lao-Sirieix P, Caldas C, Fitzgerald RC (2010) Genetic predisposition to gastro-oesophageal cancer. Curr Opin Genet Dev 20:210-217
61. Vogelstein B, Lane D, Levine AJ (2000) Surfi ng the p53 network. Nature 408:307-310
62. Birch JM, Alston RD, McNally RJ et al (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621-4628 (Pubitemid 32762434)
63. Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298-1304 (Pubitemid 24108072)
64. Chompret A (2002) The Li-Fraumeni syndrome. Biochimie 84:75-82 (Pubitemid 34477095)
65. Bougeard G, Brugieres L, Chompret A et al (2003) Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 22:840-846 (Pubitemid 36255819)
66. Easton D, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12e13. Am J Hum Genet 61:120-128 (Pubitemid 27323331)
67. Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identifi ed in a risk evaluation program. J Natl Cancer Inst 94:1365-1372 (Pubitemid 35154141)